Day: May 12, 2026

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech...

ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care

ENvue™ Navigation Platform adopted as the standard of care for bedside feeding tube placement across the integrated health networkTYLER, Texas,...

DEA’s New Marijuana Registration Questions Redefining the Cannabis Industry – And MMJ International Already Has the Answer

"As Federal Courts Review Cannabis Policy and CMS Expands Cannabinoid Access, MMJ's FDA-and-DEA-Compliant Pharmaceutical Track Record Emerges as a Potential...

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indicationsTAMPA, Fla....

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

The first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable...

error: Content is protected !!